Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Newly Diagnosed BRCA-Mutated Advanced Ovarian Cancer
NCT04598321Phase 1Terminated
- Sponsor
- Brown University
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Brown University. Primary endpoint: Determine the Preliminary Effectiveness of Talazorparib at 9 weeks. Started Mar 2021; status: terminated.
02
Drugs
talazoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04598321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598321.